

# Mark D Danese

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5778792/publications.pdf>

Version: 2024-02-01

69  
papers

3,679  
citations

257101

24  
h-index

128067

60  
g-index

70  
all docs

70  
docs citations

70  
times ranked

4173  
citing authors

#	ARTICLE	IF	CITATIONS
1	Thyroid Status, Cardiovascular Risk, and Mortality in Older Adults. JAMA - Journal of the American Medical Association, 2006, 295, 1033.	3.8	700
2	Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney International, 2005, 68, 1793-1800.	2.6	499
3	Effect of Thyroxine Therapy on Serum Lipoproteins in Patients with Mild Thyroid Failure: A Quantitative Review of the Literature*. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 2993-3001.	1.8	322
4	PTH and the Risks for Hip, Vertebral, and Pelvic Fractures Among Patients on Dialysis. American Journal of Kidney Diseases, 2006, 47, 149-156.	2.1	271
5	Estimated Life Expectancy and Income of Patients With Sickle Cell Disease Compared With Those Without Sickle Cell Disease. JAMA Network Open, 2019, 2, e1915374.	2.8	163
6	Screening for Mild Thyroid Failure at the Periodic Health Examination. JAMA - Journal of the American Medical Association, 1996, 276, 285.	3.8	151
7	Consistent Control of Mineral and Bone Disorder in Incident Hemodialysis Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2008, 3, 1423-1429.	2.2	122
8	CKDâ€“Mineral and Bone Disorder and Risk of Death and Cardiovascular Hospitalization in Patients on Hemodialysis. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 2132-2140.	2.2	94
9	Shortâ€“term and longâ€“term failure of laparoscopic splenectomy in adult immune thrombocytopenic purpura patients: A systematic review. American Journal of Hematology, 2009, 84, 743-748.	2.0	84
10	Addition of rituximab to chemotherapy alone as first-line therapy improves overall survival in elderly patients with mantle cell lymphoma. Blood, 2011, 118, 4808-4816.	0.6	81
11	Abnormal Bone and Mineral Metabolism in Kidney Transplant Patients â€“ A Review. American Journal of Nephrology, 2008, 28, 246-253.	1.4	71
12	WHEN TO TREAT MILD HYPOTHYROIDISM. Endocrinology and Metabolism Clinics of North America, 2000, 29, 399-415.	1.2	70
13	Association of a Combined Measure of Adherence and Treatment Intensity With Cardiovascular Outcomes in Patients With Atherosclerosis or Other Cardiovascular Risk Factors Treated With Statins and/or Ezetimibe. JAMA Network Open, 2018, 1, e185554.	2.8	67
14	Clinical and Economic Outcomes of Staphylococcus aureus Septicemia in ESRD Patients Receiving Hemodialysis. American Journal of Kidney Diseases, 2005, 46, 301-308.	2.1	65
15	Mortality differences among organisms causing septicemia in hemodialysis patients. Hemodialysis International, 2006, 10, 56-62.	0.4	60
16	Effect of Epoetin Alfa Dose Changes on Hemoglobin and Mortality in Hemodialysis Patients with Hemoglobin Levels Persistently below 11 g/dL. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 630-637.	2.2	49
17	Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States. Journal of Medical Economics, 2012, 15, 712-723.	1.0	49
18	Estimated burden of cardiovascular disease and value-based price range for evolocumab in a high-risk, secondary-prevention population in the US payer context. Journal of Medical Economics, 2017, 20, 555-564.	1.0	49

#	ARTICLE	IF	CITATIONS
19	Estimated Cases of Blindness and Visual Impairment from Neovascular Age-Related Macular Degeneration Avoided in Australia by Ranibizumab Treatment. PLoS ONE, 2014, 9, e101072.	1.1	43
20	Cost and mortality associated with hospitalizations in patients with immune thrombocytopenic purpura. American Journal of Hematology, 2009, 84, 631-635.	2.0	42
21	Racial differences in treatment and survival in older patients with diffuse large B-cell lymphoma (DLBCL). BMC Cancer, 2010, 10, 625.	1.1	38
22	An observational study of the prevalence and incidence of comorbid conditions in older women with breast cancer. Annals of Oncology, 2012, 23, 1756-1765.	0.6	37
23	An observational study of outcomes after initial infused therapy in Medicare patients diagnosed with chronic lymphocytic leukemia. Blood, 2011, 117, 3505-3513.	0.6	34
24	Estimating the economic burden of cardiovascular events in patients receiving lipid-modifying therapy in the UK. BMJ Open, 2016, 6, e011805.	0.8	29
25	Comparative effectiveness and cost of adding rituximab to first-line chemotherapy for elderly patients diagnosed with diffuse large B-cell lymphoma. Cancer, 2012, 118, 6079-6088.	2.0	28
26	Second-line therapy in diffuse large B-cell lymphoma (DLBCL): treatment patterns and outcomes in older patients receiving outpatient chemotherapy. Leukemia and Lymphoma, 2017, 58, 1094-1104.	0.6	26
27	Prevalence and incidence of comorbidities in elderly women with ovarian cancer. Gynecologic Oncology, 2013, 129, 346-352.	0.6	25
28	Estimating the Population Benefits and Costs of Rituximab Therapy in the United States from 1998 to 2013 Using Real-World Data. Medical Care, 2016, 54, 343-349.	1.1	23
29	Budget impact model of adding erlotinib to a regimen of gemcitabine for the treatment of locally advanced, nonresectable or metastatic pancreatic cancer. Clinical Therapeutics, 2008, 30, 775-784.	1.1	22
30	Effect of Adherence on Lifetime Fractures in Osteoporotic Women Treated With Daily and Weekly Bisphosphonates. Journal of Bone and Mineral Research, 2009, 24, 1819-1826.	3.1	22
31	Management of lipid-lowering therapy in patients with cardiovascular events in the UK: a retrospective cohort study. BMJ Open, 2017, 7, e013851.	0.8	21
32	Impact on Medical Cost, Cumulative Survival, and Cost-Effectiveness of Adding Rituximab to First-Line Chemotherapy for Follicular Lymphoma in Elderly Patients: An Observational Cohort Study Based on SEER-Medicare. Journal of Cancer Epidemiology, 2012, 2012, 1-13.	0.5	20
33	Evaluation of bleeding-related episodes in patients with immune thrombocytopenia (ITP) receiving romiplostim or medical standard of care. International Journal of Hematology, 2012, 96, 26-33.	0.7	20
34	Infused Therapy and Survival in Older Patients Diagnosed with Metastatic Breast Cancer who Received Trastuzumab. Cancer Investigation, 2011, 29, 573-584.	0.6	19
35	Health care utilization and mortality among elderly patients with myelodysplastic syndromes. Annals of Oncology, 2011, 22, 1181-1188.	0.6	19
36	Inverse Probability Weighted Least Squares Regression in the Analysis of Time-Censored Cost Data: An Evaluation of the Approach Using SEER-Medicare. Value in Health, 2012, 15, 656-663.	0.1	19

#	ARTICLE	IF	CITATIONS
37	Epidemiology and outcomes of previously undiagnosed diabetes in older women with breast cancer: an observational cohort study based on SEER-Medicare. <i>BMC Cancer</i> , 2012, 12, 613.	1.1	19
38	Evaluation of Bleeding-Related Episodes in Patients with Chronic Immune Thrombocytopenia (ITP) Treated with Romiplostim in Two Phase 3 Placebo-Controlled Clinical Trials.. <i>Blood</i> , 2009, 114, 891-891.	0.6	19
39	The association of vitamin D use with hypercalcemia and hyperphosphatemia in hemodialysis patients: a caseâ€“crossover study. <i>Pharmacoepidemiology and Drug Safety</i> , 2011, 20, 914-921.	0.9	17
40	Refining the definition of clinically important mineral and bone disorder in hemodialysis patients. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 1336-1344.	0.4	15
41	Hospitalizations in pediatric patients with immune thrombocytopenia in the United States. <i>Platelets</i> , 2016, 27, 472-478.	1.1	14
42	Systematic Literature Review of the Global Incidence and Prevalence of Myelodysplastic Syndrome and Acute Myeloid Leukemia. <i>Blood</i> , 2016, 128, 5930-5930.	0.6	14
43	The Generalized Data Model for clinical research. <i>BMC Medical Informatics and Decision Making</i> , 2019, 19, 117.	1.5	13
44	Estimating recurrences prevented from using trastuzumab in HER2-positive adjuvant breast cancer in the United States. <i>Cancer</i> , 2010, 116, 5575-5583.	2.0	10
45	Estimated Life-Years Saved in Women with HER2-Positive Metastatic Breast Cancer Receiving First-Line Trastuzumab and Pertuzumab in the United States. <i>Value in Health</i> , 2015, 18, 876-883.	0.1	10
46	DECISION ANALYSIS IN ENDOCRINOLOGY AND METABOLISM. <i>Endocrinology and Metabolism Clinics of North America</i> , 1997, 26, 89-111.	1.2	9
47	A novel approach to the evaluation of bleeding-related episodes in patients with chronic immune thrombocytopenia. <i>Current Medical Research and Opinion</i> , 2012, 28, 789-796.	0.9	9
48	The burden of immune thrombocytopenia in adults: Evaluation of the thrombopoietin receptor agonist romiplostim. <i>Journal of Medical Economics</i> , 2012, 15, 956-976.	1.0	9
49	The prevalence, low-density lipoprotein cholesterol levels, and treatment of patients at very high risk of cardiovascular events in the United Kingdom: a cross-sectional study. <i>Current Medical Research and Opinion</i> , 2018, 34, 1441-1447.	0.9	8
50	Racial and Ethnic Variability in the Prevalence and Incidence of Comorbidities Associated with Gastric Cancer in the United States. <i>Journal of Gastrointestinal Cancer</i> , 2016, 47, 168-181.	0.6	7
51	Survival in elderly follicular lymphoma patients who receive frontline chemo-immunotherapy. <i>American Journal of Hematology</i> , 2010, 85, 963-967.	2.0	6
52	Methods for estimating costs in patients with hyperlipidemia experiencing their first cardiovascular event in the United Kingdom. <i>Journal of Medical Economics</i> , 2017, 20, 931-937.	1.0	6
53	A comparison of mixture cure fraction models to traditional parametric survival models in estimation of the cost-effectiveness of nivolumab for relapsed small cell lung cancer. <i>Journal of Medical Economics</i> , 2021, 24, 79-86.	1.0	6
54	The rate, cost and outcomes of parathyroidectomy in the united states dialysis population from 2016â€“2018. <i>BMC Nephrology</i> , 2022, 23, .	0.8	6

#	ARTICLE	IF	CITATIONS
55	Treatment patterns, survival, and hospitalization in adult patients with acute lymphoblastic leukemia: an observational cohort study using SEER Medicare data. <i>Leukemia and Lymphoma</i> , 2019, 60, 2015-2024.	0.6	5
56	Facility-level CKD-MBD composite score and risk of adverse clinical outcomes among patients on hemodialysis. <i>BMC Nephrology</i> , 2016, 17, 166.	0.8	3
57	Real World Use and Effects of Calcimimetics in Treating Mineral and Bone Disorder in Hemodialysis Patients. <i>American Journal of Nephrology</i> , 2020, 51, 815-822.	1.4	3
58	Fibroblast growth factor 23 as a risk factor for cardiovascular events and mortality in patients in the EVOLVE trial. <i>Hemodialysis International</i> , 2021, 25, 78-85.	0.4	3
59	Association Between Granulocyte Colony-Stimulating Factor (G-CSF) Use and Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) Among Elderly Patients with Breast, Lung, or Prostate Cancer. <i>Advances in Therapy</i> , 2022, 39, 2778-2795.	1.3	3
60	Societal Costs of Sickle Cell Disease in the United States. <i>Blood</i> , 2018, 132, 4706-4706.	0.6	2
61	Patterns Of Care, Survival, and Costs Of Second-Line Treatment In Medicare Beneficiaries With Diffuse Large B-Cell Lymphoma (DLBCL). <i>Blood</i> , 2013, 122, 2936-2936.	0.6	2
62	Treatment patterns and outcomes in older patients with advanced malignant pleural mesothelioma: Analyses of Surveillance, Epidemiology, and End Results—Medicare data. <i>Cancer Reports</i> , 2021, , e1568.	0.6	2
63	Real-world outcomes with second-line therapy in advanced esophageal squamous cell carcinoma using SEER-Medicare data. <i>Future Oncology</i> , 2022, 18, 927-936.	1.1	2
64	Quality adjusted life year gains associated with administration of recombinant tissue-type plasminogen activator for treatment of acute ischemic stroke: 1998–2011. <i>International Journal of Stroke</i> , 2016, 11, 198-205.	2.9	1
65	Evaluation of Bleeding-Related Episodes in Patients with Chronic Immune Thrombocytopenic Purpura (ITP) Receiving Romiplostim or Medical Standard of Care.. <i>Blood</i> , 2009, 114, 1311-1311.	0.6	1
66	Initial and Long-Term Outcomes of Splenectomy in Adult Immune Thrombocytopenic Purpura (ITP) Patients: A Systematic Review and Meta-Analysis.. <i>Blood</i> , 2007, 110, 1321-1321.	0.6	1
67	Should Physicians Screen for Mild Thyroid Failure?-Reply. <i>JAMA - Journal of the American Medical Association</i> , 1996, 276, 1550.	3.8	0
68	More on Screening for Mild Thyroid Failure-Reply. <i>JAMA - Journal of the American Medical Association</i> , 1997, 277, 459.	3.8	0
69	Longitudinal evaluation of treatment patterns, risk factors and outcomes in patients with cardiovascular disease treated with lipid-lowering therapy in the UK. <i>BMJ Open</i> , 2022, 12, e055015.	0.8	0